Patents by Inventor Julien Bouley

Julien Bouley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sialylated fetuin-A as a marker of immunotherapy efficacy
    Patent number: 10884002
    Abstract: The invention concerns the identification of specific polypeptides, fragments variants thereof which can be used as markers for the efficacy of immunotherapy, particular for predicting responsiveness of a patient to immunotherapy.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: January 5, 2021
    Assignee: STALLERGENES
    Inventors: Vincent Lombardi, Noémie Caillot, Emmanuel Nony, Philippe Moingeon, Véronique Bodo, Julien Bouley
  • Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy
    Patent number: 10190166
    Abstract: The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector T cell response, and methods of determining response to immunotherapy.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: January 29, 2019
    Assignee: STALLERGENES
    Inventors: Philippe Moingeon, Aline Zimmer, Julien Bouley, Laurent Mascarell, Emmanuel Nony
  • Biomarkers of immunotherapy efficacy
    Patent number: 10101341
    Abstract: The invention relates to proteins for use as markers for the efficacy of sublingual immunotherapy. In particular, the proteins may be used to predict the responsiveness of a patient to immunotherapy. The invention may find use in selecting patients as suitable candidates for immunotherapy.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: October 16, 2018
    Assignee: STALLERGENES
    Inventors: Véronique Bodo, Philippe Moingeon, Julien Bouley, Emmanuel Nony, Hélène Moussu, Karine Jain
  • Recombinant Der P 2 expressed in Pichia Pastoris as a “natural-like” allergen for immunotherapy and diagnostic purposes
    Patent number: 9868770
    Abstract: The present invention concerns a method for producing a recombinant Dermatophagoides pteronyssinus 2 protein (rDer p 2), comprising the steps of cultivating a Pichia pastoris yeast strain previously transformed with a rDer p 2 coding sequence, and isolating the rDer p 2 protein from said Pichia pastoris yeast strain. The invention also relates to compositions and kits comprising the rDer p 2 protein for therapeutic or diagnostic use.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: January 16, 2018
    Assignee: STALLERGENES
    Inventors: Véronique Bordas, Laetitia Bussieres, Sabi Airouche, Sophie Tourdot, Emmanuel Nony, Philippe Moingeon, Julien Bouley
  • SIALYLATED FETUIN-A AS A MARKER OF IMMUNOTHERAPY EFFICACY
    Publication number: 20170370946
    Abstract: The invention concerns the identification of specific polypeptides, fragments variants thereof which can be used as markers for the efficacy of immunotherapy, particular for predicting responsiveness of a patient to immunotherapy.
    Type: Application
    Filed: November 23, 2015
    Publication date: December 28, 2017
    Inventors: Vincent LOMBARDI, Noémie CAILLOT, Emmanuel NONY, Philippe MOINGEON, Véronique BODO, Julien BOULEY
  • METHODS FOR IDENTIFYING DENDRITIC CELL SUBSETS, FOR DETERMINING IF A PATIENT IS DEVELOPING A REGULATORY OR AN EFFECTOR IMMUNE RESPONSE, AND FOR DETERMINING RESPONSE TO IMMUNOTHERAPY
    Publication number: 20140377761
    Abstract: The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector T cell response, and methods of determining response to immunotherapy.
    Type: Application
    Filed: September 5, 2012
    Publication date: December 25, 2014
    Applicant: STALLERGENES S.A.
    Inventors: Philippe Moingeon, Aline Zimmer, Julien Bouley, Laurent Mascarell, Emmanuel Nony
  • BIOMARKERS OF IMMUNOTHERAPY EFFICACY
    Publication number: 20140112955
    Abstract: The invention relates to proteins for use as a marker for the efficacy of sublingual immunotherapy. In particular, the proteins may be used to predict the responsiveness of a patient to immunotherapy. The invention may find use in selecting patients as suitable candidates for immunotherapy.
    Type: Application
    Filed: April 6, 2012
    Publication date: April 24, 2014
    Applicant: STALLERGENES S.A.
    Inventors: Véronique Bodo, Philippe Moingeon, Julien Bouley, Emmanuel Nony, Héléne Moussu, Karine Jain
  • Recombinant Der P 2 Expressed in Pichia Pastoris as a "Natural-Like" Allergen for Immunotherapy and Diagnostic Purposes
    Publication number: 20110293665
    Abstract: The present invention concerns a method for producing a recombinant Dermatophagoides pteronyssinus 2 protein (rDer p 2), comprising the steps of cultivating a Pichia pastoris yeast strain previously transformed with a rDer p 2 coding sequence, and isolating the rDer p 2 protein from said Pichia pastoris yeast strain. The invention also relates to compositions and kits comprising the rDer p 2 protein for therapeutic or diagnostic use.
    Type: Application
    Filed: May 17, 2011
    Publication date: December 1, 2011
    Inventors: Véronique BORDAS, Laetitia Bussieres, Sabi Airouche, Sophie Tourdot, Emmanuel Nony, Philippe Moingeon, Julien Bouley